December 29, 2023 Regulatory Report from the Extraordinary General Meeting of Promore Pharma AB held on 29 December 2023
December 21, 2023 Regulatory Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description
December 8, 2023 Regulatory Update on reverse acquisition – PMD completes private placement and major shareholder receives exemption from mandatory bid requirements
November 29, 2023 Regulatory Correction: NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROMORE PHARMA AB (PUBL)
November 29, 2023 Regulatory Promore Pharma AB intends to carry out a reverse acquisition of PMD Device Solutions AB
October 5, 2023 Regulatory Report from the Extraordinary General Meeting of Promore Pharma AB held on 5 October 2023
June 27, 2023 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
June 22, 2023 Regulatory Promore Pharma reduces costs and explores the conditions for a reverse acquisition
April 20, 2023 Non Regulatory Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05
April 20, 2023 Regulatory Promore Pharma reports outcome from clinical Phase II study with ensereptide
February 27, 2023 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022
February 27, 2023 Non Regulatory Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide